Clinical Trials

LACOG 0213 - AUGMENT

Title

A phase 3, double-blind randomized study to compare the efficacy and safety of rituximab plus lenalidomide (CC-5013) versus rituximab plus placebo in subjucts with relapsed/refractory indolent lymphoma.

Primary Objective

To evaluate the efficacy (PFS) and safety of rituximab plus lenalidomide combination therapy in subjects with relapsed/refratory indolent lumphoma.

Design

This is a phase 3 multicenter, double-blind, randomized study is designed to evaluate the efficacy and safety of rituximab plus lenalidomide versus rituximab plus placebo.

Sample size: 350

Status: Open

LACOG Study Coordinator: Phillip Scheinberg

Sponsor: Celgene 

LACOG 0213 - AUGMENT

Registry

Clinicaltrials.gov NCT01938001

Contact

lacog@lacog.org.br

Phone: 55 51 3384 5334